Drugs in development for the treatment of osteoporosis:Raloxifene
Taga, M.
Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 3): 572-580
2002
ISSN/ISBN: 0047-1852 PMID: 11979956 Document Number: 547135
Document emailed within 1 workday
Related Documents
Gorai, I. 2002: Drugs in development for the treatment of osteoporosis: Tibolone Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 3): 552-571Ohta, H. 2008: Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis Clinical Calcium 18(10): 1442-1450
Hasegawa, M.; Ichimura, S.; Satomi, K. 2010: Effects of SERMs on bone health. the evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers Clinical Calcium 20(3): 413-420
Oliaro, A. 1998: Raloxifene: a new molecule for the prevention of menopausal osteoporosis Minerva Ginecologica 50(3): XII-XIII
Miskić, B.; Bistrović, D.; Cosić, V.; Leko, N.; Balen-Jandrić, M.; Balen, I.; Samardzić, P.; Miskić, D. 2003: Effect of raloxifene on lowering lipid parameters in patients with osteoporosis International Journal of Clinical Pharmacology Research 23(4): 107-110
Ciesielska-Kopacz, N.; Kos-Kudła, B.; Pluskiewicz, W. 1998: The influence of thyroid diseases and their treatment on the development of osteoporosis Przeglad Lekarski 55(5): 271-273
Soen, S. 2007: First choice drug for treatment of osteoporosis and the strategic points for choice of drugs Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 9): 325-328
Martiradonna, A.; Terlizzi, N.; D'Amore, M.; Pallante, R.; Carrozzo, M. 1981: Experimental osteoporosis caused by calcium deficiency in rats: treatment with calcium salts and synthetic anabolic drugs La Clinica Terapeutica 97(6): 587-604
Asakura, H.; Sugimura, K. 1999: Present states of development in new drugs and treatment of inflammatory bowel disease Nihon Rinsho. Japanese Journal of Clinical Medicine 57(11): 2490-2495
2006: Osteoporosis drugs and jaw problems. Weighing your risks Mayo Clinic Health Letter 24(12): 6
Halse, J.; Falch, J.; Haug, E.; Jorde, R.; Nesheim, B.I.; Nordal, K.P.; Skjaeraasen, J.; Aanderud, S. 1995: Osteoporosis drugs prescribed on blue forms! Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 115(24): 3050-3051
De, D.P. 1994: Current thoughts about the mechanism of drug addiction and the possibility of development of new drugs in its treatment Journal of the Indian Medical Association 92(7): 239-240
Reginster, J.Y. 1996: Prevention of postmenopausal osteoporosis: estrogens and nonhormonal drugs Revue Medicale de Liege 51(10): 649-653
Ammann, P.; Rizzoli, R.; Bonjour, J.P. 1999: Animal models for the preclinical testing of drugs against osteoporosis Revue du Rhumatisme 66(11): 532-533
Aksaranugraha, S. 2011: Observation: application and advantages of BMK in osteoporosis by monitoring the dose of antiresorptive drugs with CTx Journal of the Medical Association of Thailand 94(Suppl 5): S63-S70
Beerhorst, K.; Huvers, F.C.; Renier, W.O. 2005: Severe early onset osteopenia and osteoporosis caused by antiepileptic drugs Netherlands Journal of Medicine 63(6): 222-226
Minakuchi, M.; Tanaka, E.; Inoue, T.; Sakuramoto, M.; Maeda, Y.; Maniwa, K.; Taguchi, Y. 2005: An adult case of cervico-mediastinal lymph nodes tuberculosis followed by the development of pulmonary lesions during the treatment with antituberculous drugs Kekkaku: 80(1): 19-23
Woodward, A.H.; Jowsey, J. 1974: Estrogens and development of immobilization osteoporosis in rats Surgical Forum 25: 480-481
Rygnestad, T. 1992: Development of physostigmine from a poisonous plant to an antidote. one of the most important drugs in the development of modern medicine? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 112(10): 1300-1303
Wynn, R.L. 2000: Osteoporosis, alveolar bone loss, and drug development General Dentistry 48(3): 218-222; 224-225